Rhumbline Advisers Oramed Pharmaceuticals Inc. Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 1,830 shares of ORMP stock, worth $4,648. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,830
Previous 1,830
-0.0%
Holding current value
$4,648
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ORMP
# of Institutions
59Shares Held
5.69MCall Options Held
8.3KPut Options Held
2.7K-
Murchinson Ltd. Toronto, A61.38MShares$3.5 Million0.36% of portfolio
-
Bml Capital Management, LLC Zionsville, IN844KShares$2.15 Million1.65% of portfolio
-
Boothbay Fund Management, LLC New York, NY690KShares$1.75 Million0.05% of portfolio
-
Morgan Jess S & CO Inc366KShares$930,6582.07% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA344KShares$874,8720.0% of portfolio
About ORAMED PHARMACEUTICALS INC.
- Ticker ORMP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,100
- Market Cap $98.6M
- Description
- Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...